PDF herunterladen
Semin Thromb Hemost 2006; 32(6): 626-635
DOI: 10.1055/s-2006-949668
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Comparative Analysis and Classification of von Willebrand Factor/Factor VIII Concentrates: Impact on Treatment of Patients with von Willebrand Disease

Ulrich Budde1 , Hubert J. Metzner2 , Heinz-Georg Müller3
  • 1Coagulation Laboratory, Laboratory Association Prof. Arndt and Partners, Hamburg, Germany
  • 2ZLB Behring GmbH, Preclinical R&D, Marburg, Germany
  • 3ZLB Behring GmbH, Quality Control, Marburg, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. September 2006 (online)

    Lizenzen und Reprints

ABSTRACT

von Willebrand disease (vWD) is a bleeding disorder that results from defects in the quality or quantity of von Willebrand factor (vWF), a glycoprotein essential for normal thrombus formation. vWF circulates in plasma as multimers in sizes ranging up to 20,000 kd. The high molecular weight vWF (HMWvWF) multimers are most essential for primary hemostasis, whereas the lower molecular weight multimers are less functionally active. For many patients, the treatment of choice is factor replacement with a vWF/FVIII concentrate, preferably one with a high content of HMWvWF multimers. Given that the commercially available vWF/FVIII concentrates seem to differ substantially in their biochemical properties as well as in their clinical efficacy, we did a comparative study with 12 vWF/FVIII concentrates to investigate content and activities of FVIII and vWF, as well as the content of HMWvWF multimers. The content of HMWvWF multimers varied considerably among the 12 concentrates. The specific vWF activities, as assessed by ristocetin cofactor activity (vWF:RCo) and collagen-binding activity (vWF:CB), correlated well with the HMWvWF content of the products. Of the products tested, Haemate P/Humate-P had the highest content of HMWvWF multimers (with a multimer pattern closest to that of normal human plasma), the highest specific vWF activities, and the highest values of vWF:RCo and vWF:CB per unit of FVIII:coagulant (C). The goal of bleeding prophylaxis and treatment in type 2, severe type 1, and type 3 vWD patients is to normalize vWF activities (vWF:RCo and vWF:CB) and FVIII:C preferentially by vWF/FVIII concentrates containing the high vWF multimers and a high vWF:RCo/FVIII ratio to achieve normal primary and secondary hemostasis. Based on the present study of a comparative analysis of currently available vWF/FVIII concentrates, a classification of vWF/FVIII products is proposed.

KEYWORDS

Hemostasis - von Willebrand disease (vWD) - von Willebrand factor (vWF) - factor VIII - vWF multimers - ristocetin cofactor activity - collagen-binding activity - classification of vWF products

REFERENCES

  • 1 Keeney S, Cumming A M. The molecular biology of von Willebrand disease.  Clin Lab Haematol. 2001;  23 209-230
    CrossrefPubMedSuche in Google Scholar
  • 2 Favaloro E J. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.  Blood Rev. 1999;  13 185-204
    CrossrefPubMedSuche in Google Scholar
  • 3 Furlan M. Von Willebrand factor: molecular size and functional activity.  Ann Hematol. 1996;  72 341-348
    CrossrefPubMedSuche in Google Scholar
  • 4 Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates.  Haemophilia. 2004;  10 243-249
    CrossrefPubMedSuche in Google Scholar
  • 5 Sadler J E, Mannucci P M, Berntorp E et al.. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost. 2000;  84 160-174
    Thieme ConnectPubMedSuche in Google Scholar
  • 6 Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease.  Semin Thromb Hemost. 2002;  28 173-189
    PubMedSuche in Google Scholar
  • 7 Mannucci P M, Bloom A L, Larrieu M J, Nilssen J M. Atherosclerosis and von Willebrand factor: I. Prevalence of von Willebrand's disease in Western Europe and Israel.  Br J Haematol. 1984;  57 163-169
    PubMedSuche in Google Scholar
  • 8 Sadler J E, Mannucci P M, Berntorp E et al.. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost. 2000;  84 160-174
    Thieme ConnectPubMedSuche in Google Scholar
  • 9 Castaman G. Epidemiology and diagnosis of von Willebrand's disease.  Haematologica. 2001;  86(suppl 2) 1-9
    PubMedSuche in Google Scholar
  • 10 Federici A B, Mannucci P M. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.  Haemophilia. 1998;  4(suppl 3) 7-10
    CrossrefPubMedSuche in Google Scholar
  • 11 Ruggeri Z M. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation.  Baillieres Best Pract Res Clin Haematol. 2001;  14(2) 257-279
    CrossrefPubMedSuche in Google Scholar
  • 12 Tsai H-M. Shear stress and von Willebrand factor in health and disease.  Semin Thromb Hemost. 2003;  29 479-488
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Sugimoto M, Matsui H, Mizuno T et al.. Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions.  Blood. 2003;  101 915-920
    CrossrefPubMedSuche in Google Scholar
  • 14 Favaloro E J, Bukuya M, Martinneli T et al.. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.  Thromb Haemost. 2002;  87 466-476
    Thieme ConnectPubMedSuche in Google Scholar
  • 15 Metzner H J, Hermentin P, Cuesta-Linker T et al.. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis.  Haemophilia. 1998;  4(suppl 3) 25-32
    PubMedSuche in Google Scholar
  • 16 Neugebauer B M, Goy C, Budek I, Seitz R. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.  Semin Thromb Hemost. 2002;  28 139-147
    Thieme ConnectPubMedSuche in Google Scholar
  • 17 Favaloro E J. Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand's disorder.  Baillieres Best Pract Res Clin Haematol. 2001;  14(2) 299-319
    PubMedSuche in Google Scholar
  • 18 Federici A B, Castaman G, Mannucci P M. Guidelines for the diagnosis and management of von Willebrand disease in Italy.  Haemophilia. 2002;  8 607-621
    CrossrefPubMedSuche in Google Scholar
  • 19 Budde U, Schneppenheim R, Plendi H et al.. Luminographic detection of von Willebrand factor multimers in agarose gels on nitrocellulose membranes.  Thromb Haemost. 1990;  63 312-315
    PubMedSuche in Google Scholar
  • 20 Favaloro E J. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrand's disease (VWD), and discrimination of VWD subtypes, depends on collagen source.  Thromb Haemost. 2000;  83 127-135
    PubMedSuche in Google Scholar
  • 21 Scharrer I. Diagnosis and management of coagulation disorders in orthopedic surgery.  Orthopade. 1999;  28 316-322
    PubMedSuche in Google Scholar
  • 22 Berntorp E. Von Willebrand factor containing factor VIII concentrates.  Haemophilia. 1999;  5(suppl 2) 60-63
    CrossrefPubMedSuche in Google Scholar
  • 23 Goudemand J, Scharrer I, Berntorp E et al.. Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods.  J Thromb Haemost. 2005;  3 1-9
    CrossrefPubMedSuche in Google Scholar
  • 24 Barrowcliffe T W. Recommendation for the assay of high-purity factor VIII concentrtates.  Thromb Haemost. 1993;  70 876-877
    PubMedSuche in Google Scholar

Ulrich BuddeM.D. 

Coagulation Laboratory, Laboratory Association Prof. Arndt and Partners

Lademannbogen 61-63, D 22339 Hamburg, Germany

eMail: budde@labor-arndt-partner.de